Trial Profile
Use of GL-ONC1 in Patients With Advanced Cancers With No Standard of Care
Status:
Suspended
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Olvimulogene nanivacirepvec (Primary)
- Indications Acute myeloid leukaemia; Cancer; Solid tumours
- Focus Expanded access; Therapeutic Use
- Sponsors Genelux Corporation
- 29 Jun 2023 Status changed from completed to suspended.
- 30 Jul 2019 Status changed from recruiting to completed.
- 07 Feb 2018 New trial record